Evidence map›Paper›PMID 36593601›Full record

ArticleBMJ case reports2022

Chalazion in a patient with multiple myeloma treated with bortezomib.

Bipin Ghimire, Yuko Hamajima, Lorena Carbajal-Carballo, Nwabundo Anusim

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 70% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Bipin GhimireDepartment of Internal Medicine, Beaumont Hospitals, Royal Oak, Michigan, USA.
Yuko HamajimaDepartment on Oncology, University of Texas at Austin Dell Seton Medical Center, Austin, Texas, USA.
Lorena Carbajal-CarballoDepartment of Oncology, University of Texas at Austin Dell Medical School, Austin, Texas, USA.
Nwabundo AnusimDepartment of Oncology, University of Texas at Austin Dell Medical School, Austin, Texas, USA nwabundo.anusim@austin.utexas.edu.ORCID http://orcid.org/0000-0002-6941-8312
The University of Texas at Austin · USBeaumont Hospital, Royal Oak · USSeton Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a case of a woman in her early 60s with multiple myeloma who, while undergoing treatment with cyclophosphamide, bortezomib and dexamethasone (CyBorD), noticed a whitish nodular swelling on the eyelid. This occurred after one cycle of CyBorD and on subsequent treatment, it also involved the contralateral eyelid. The lesions were initially managed with conservative measures by applying warm compresses, but the lesions progressively increased in size. CyBorD was discontinued and topical antibiotics and anti-inflammatories were initiated, resulting in a decrease in size of the lesions. On resolution of symptoms, she was rechallenged with CyBorD, and symptoms did not recur. The temporal relationship between bortezomib and the development of chalazion is based on connection and no association has been proven.

Indexed as

ChalazionMultiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsBortezomibCyclophosphamideDexamethasoneFemaleHumansNeoplasm Recurrence, LocalRetrospective StudiesBortezomibCyclophosphamideDexamethasoneEyeHaematology (drugs and medicines)

Identifiers

PMID36593601
PMCPMC9730351
OpenAlexW4311167554

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.